This ADC product is comprised of an Anti-CD33 antibody (clone hP67.6) conjugated via a AcBut linker to Calicheamicin. The Calicheamicin is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, Calicheamicin binds to DNA, causes DNA damage.
CD33 or Siglec-3 is a transmembrane receptor expressed on cells of myeloid lineage. It is usually considered myeloid-specific, but it can also be found on some lymphoid cells. It binds sialic acids, therefore is a member of the SIGLEC family of lectins.
ADC Antibody
Overview
Anti-CD33 lgG4κ Antibody, clone # hP676
Generic name
gemtuzumab
Clone #
hP676
Species Reactivity
Human
ADC Linker
Name
AcBut (4-(4-acetylphenoxy)butanoic acid)
Description
Acid-labile linkers, belonging to chemically cleavable linkers, are designed based on a pH-dependent release mechanism and remain intact during systemic circulation in the blood's neutral pH environment (pH 7.3–7.5) but to undergo hydrolysis and release drug once the ADC is internalized into mildly acidic endosomal (pH 5.0–6.5) and lysosomal (pH 4.5–5.0) compartments of the cell.
ADC payload drug
Name
Calicheamicin
Description
Calicheamicin,produced by prokaryotic microorganisms, are a group of DNA cleaving agents with similar structure that binds in the minor grove of DNA in a relatively sequence-specific manner.